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Original Study

Treatment Patterns and Blood Counts in Patients
With Polycythemia Vera Treated With
Hydroxyurea in the United States: An Analysis
From the REVEAL Study
Michael R. Grunwald,1 David J. Kuter,2 Ivy Altomare,3 John M. Burke,4
Aaron T. Gerds,5 Mark A. Walshauser,6 Michael R. Savona,7 Brady Stein,8
Stephen T. Oh,9 Philomena Colucci,10 Shreekant Parasuraman,10
Dilan Paranagama,10 Ruben Mesa11
Abstract
National guidelines support the use of hydroxyurea (HU) in high-risk patients with polycythemia vera (PV).
In this study, we investigated HU treatment patterns in patients with PV. Of patients who received HU for
‡ 3 months, 32.3% had dose adjustments, 23.7% had dose interruptions, and 18.6% discontinued HU. These
results emphasize the need for active management of patients with PV.
Background: Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or
those with some other clinical indication for cytoreduction. Patients and Methods: REVEAL is a prospective,
observational study designed to collect data pertaining to demographics, disease burden, clinical management,
patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this
analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of
discontinuation, death, or data cutoff. Results: Of the 1381 patients who received HU for  3 months, the median HU
exposure was 23.6 months (range, 3.1-38.5 months). The most common maximum daily HU doses were 1000 mg
(30.6%) and 500 mg (30.1%); only 6.4% received  2 g/d HU. Approximately one-third (32.3%) of patients had dose
adjustments, 23.8% had dose interruptions, and 257 (18.6%) discontinued HU. The most common reasons for HU
discontinuations and interruptions were adverse events/intolerance (37.1% and 54.5%, respectively) and lack of efﬁcacy (35.5% and 22.1%, respectively). Of those who received HU for  3 months, 57.1% had hematocrit values
> 45% on  1 occasion, 33.1% continued to receive phlebotomies, and 27.4% had uncontrolled myeloproliferation.
Conclusion: The results of this analysis emphasize the need for active management of patients with PV with appropriate
HU dose titration to maintain blood count control while monitoring for signs and symptoms of HU intolerance.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 20, No. 4, 219-25 ª 2019 The Author(s). Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cytopenia, Hematocrit, Myeloproliferative neoplasm, Observational study, Prospective
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HU Treatment Patterns and Blood Counts in PV
Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm associated with erythrocytosis, increased risk of thrombosis, and symptoms including fatigue, early satiety, abdominal discomfort, and
pruritus.1,2 The primary goals of risk-adapted therapy for patients
with PV include prevention of thromboembolism, reduction of
symptom burden, and reduction of bleeding risk.3-5
The European LeukemiaNet (ELN) response criteria for PV
include hematocrit (HCT) < 45%.6,7 Hydroxyurea (HU) is the
most commonly used ﬁrst-line cytoreductive medication for patients
with high-risk PV. The CYTO-PV study was a prospective, randomized study that demonstrated that an HCT target < 45% was
associated with a reduced rate of thrombotic complications.8
An elevated white blood cell (WBC) count has also been implicated
in the increased risk of thrombosis in patients with PV. A multivariate,
time-dependent sub-analysis of CYTO-PV showed increased risk of
thrombosis in patients with WBC count > 11  109/L, which has
been conﬁrmed by several similar analyses.9-11 However, unlike
HCT control, control of leukocytosis has not been shown to reduce
thrombosis risk in a prospective study.
The ELN and National Comprehensive Cancer Network
(NCCN) Guidelines support the use of HU or interferons in patients with an indication for cytoreductive therapy to achieve and
maintain HCT < 45%.4,5 Although in the United States, HU is
more commonly used, HU or interferon can lead to HCT control,
and both may be supplemented with phlebotomy to achieve
HCT < 45%.
A proportion of patients who receive HU fail to achieve HCT
and other blood count control.12 Moreover, approximately onequarter of patients will develop resistance and/or intolerance to
HU. The ELN convened a group of experts to develop a consensus
deﬁnition of clinical resistance and intolerance to HU in patients
with PV (Table 1).13 Of note, this consensus deﬁnition was
developed for use in clinical research and was not entirely based on
rigorously designed and controlled trials. A modiﬁed version of the
deﬁnition has been used in clinical trials to identify patients with PV
who are resistant/intolerant to HU.14 In addition, the deﬁnition has
been included in NCCN Guidelines, where it is intended to help
health care providers identify high-risk patients who have a potential
indication for a change in cytoreductive therapy. Although this
deﬁnition may not have been universally incorporated into clinical
practice, the criteria contained within the deﬁnition can provide a
useful framework to examine and discuss the treatment patterns of
HU in patients with PV.
REVEAL (ClinicalTrials.gov, NCT02252159) is a prospective,
observational study of patients with PV in the United States,
designed to collect data pertaining to the demographics, disease
burden, clinical management, patient-reported outcomes, and
health care resource utilization of these patients. This analysis of
REVEAL characterized HU treatment patterns, including dosing,
blood count control, and HU intolerance.

Patients and Methods
This is an exploratory, longitudinal sub-analysis of data from
REVEAL. Central (Sterling) and investigative site institutional review board approvals were obtained as applicable. The current
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analysis includes data collected from July 22, 2014, to May 18,
2017. This study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki, and all
patients provided written informed consent.

Patients
Patients were aged  18 years, had a clinical diagnosis of PV
established by their treating physician, and were willing and able to
complete questionnaires, either alone or with minimal assistance.
Patients must have been under physician supervision for management of their PV. Patients who were participating in an active,
blinded clinical trial; had a life expectancy of < 6 months; had a
diagnosis of myeloﬁbrosis, acute myeloid leukemia, or myelodysplastic syndrome; had a history of, or active plan to proceed to,
allogeneic hematopoietic stem cell transplant within 3 months of
enrollment; or had a splenectomy were excluded. All decisions
regarding patient care were made by the treating physician.

Data Collection
At the time of enrollment, data pertaining to demographics, PV
diagnosis, disease course, medical history, and family history were
obtained from patient charts and entered into an electronic clinical
research form. Retrospective data were collected up to 6 months
prior to enrollment, whereas prospective data on PV disease course,
phlebotomy procedures, laboratory results, and medications were
collected from the time of enrollment.
To ensure maximum data capture for enrolled patients, an index
date was deﬁned as 6 months prior to the date of enrollment for each
patient. A post-index period was deﬁned as the time from index to
patient discontinuation from the study, death, or data cutoff, whichever
came ﬁrst. Patients who had received HU continuously for  3 months
during the post-index period were included in the analyses. All assessments were done after the ﬁrst 3 months of continuous HU, and
while receiving HU during the post index period.

HU Treatment Patterns
During the post-index period, HU treatment patterns, including
duration of exposure, maximum daily dose, duration of maximum
daily dose, dose changes, dose interruptions (deﬁned as interruption
> 14 days), and permanent discontinuations (deﬁned as HU dose
discontinued and not restarted during the post index period) were
compiled. The reasons for dose changes, interruptions, and discontinuations were also summarized. Physicians were asked to
choose from 6 options to describe the reasons for treatment
discontinuation: adverse events, disease progression, lack of efﬁcacy,
physician decision, patient decision, or other.

Assessments During HU Treatment
During HU treatment, blood counts were examined relative to
the ELN deﬁnition of response and resistance/intolerance criteria
(Table 1) irrespective of HU dose; health care providers were not
required to use the ELN deﬁnition and may or may not have been
aware of the ELN deﬁnition when making treatment decisions. The
following assessments were made after 3 months of HU exposure
during the post-index period: proportion of patients with elevated
HCT values (HCT > 45%) with or without phlebotomies;
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Table 1 Deﬁnition of Resistance/Intolerance to HU in Patients With PV13
1. Need for phlebotomy to keep HCT < 45% after 3 months of  2 g/d HU, OR
2. Uncontrolled myeloproliferation (ie, PLT count > 400  109/L AND WBC count > 10  109/L) after 3 months of  2 g/d HU, OR
3. Failure to reduce massive splenomegalya by > 50% as measured by palpation OR failure to completely relieve symptoms related to splenomegaly after 3 months
of  2 g/d HU, OR
4. ANC < 1.0  109/L OR PLT count < 100  109/L OR HGB < 10 g/dL at the lowest dose of HU required to achieve a complete or partial clinicohematologic
response,b OR
5. Presence of leg ulcers or other unacceptable HU-related nonhematologic toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis,
or fever at any dose of HU
Abbreviations: ANC ¼ absolute neutrophil count; HCT ¼ hematocrit; HGB ¼ hemoglobin; HU ¼ hydroxyurea; PLT ¼ platelet; PV ¼ polycythemia vera; WBC ¼ white blood cell.
a
Organ extending > 10 cm below the costal margin.
b
Complete response deﬁned as HCT < 45% without phlebotomy, PLT count  400  109/L, WBC count  10  109/L, and no disease-related symptoms. Partial response deﬁned as
HCT < 45% without phlebotomy or response in  3 other criteria.

proportion of patients continuing to require phlebotomies; proportion of patients with uncontrolled myeloproliferation (ie, platelet
count > 400  109/L and WBC count > 10  109/L); and
presence of splenomegaly as assessed by palpation. The proportion
of patients with HCT < 45% and cytopenias, deﬁned as leukopenia
(WBC count < 4  109/L), thrombocytopenia (platelet
count < 100  109/L), anemia (hemoglobin < 10 g/dL), and
neutropenia (absolute neutrophil count < 1  109/L), was evaluated in patients who had a minimum of 2 HCT results. All patients
with laboratory values during the post index period while on HU
were included in the analyses. Non-hematologic adverse events
attributed to HU were also summarized.

Table 2 Baseline Demographics and Disease Characteristics
at Time of Enrollment

Variable

All Patients
(N [ 2510)

Received HU
for ‡ 3 Months
(n [ 1381)

Median age (range), y

67.0 (22.0-95.0)

69.0 (26.0-94.0)

Female

1150 (45.8)

695 (50.3)

Male

1360 (54.2)

686 (49.7)

2237 (89.1)

1235 (89.4)

143 (5.7)

81 (5.9)

Sex, n (%)

Race, n (%)
White
African American
Asian

37 (1.5)

19 (1.4)

Other/no information

93 (3.7)

46 (3.3)

4.0 (0.0-56.3)

4.3 (0.0-36.5)

<1

543 (21.6)

270 (19.6)

1 to < 3

500 (19.9)

270 (19.6)

3 to < 5

391 (15.6)

230 (16.7)

1051 (41.9)

597 (43.2)

25 (1.0)

14 (1.0)

High

1939 (77.3)

1165 (84.4)

Low

571 (22.7)

216 (15.6)

Median disease duration
(range), y
Disease duration, y, n (%)

5
Missing
Risk category at
enrollment, n (%)

Abbreviation: HU ¼ hydroxyurea.

All analyses were exploratory in nature and were evaluated with
descriptive statistics. Statistical analyses were performed using SAS
statistical software (SAS Institute, Cary, NC).

Results
In total, 2510 patients were enrolled from 227 sites; 1432
received HU, of whom 1381 received HU for  3 months and were
evaluable in the post-index period (Table 2). The median age was
69 years (range, 26-94 years), 49.7% were male, and 89.4% were
white. The median disease duration was 4.3 years (range, 0-36.5
years). At the time of enrollment, 84.4% of all patients treated with
HU for  3 months had high-risk PV, deﬁned as age  60 years
and/or prior history of thrombosis.

HU Treatment Patterns
The median exposure to HU during the post-index period
was 23.6 months (range, 3.1-38.5 months). Most (72.1%)
patients received between 500 and 1000 mg/d HU; the most
common maximum daily HU doses were 1000 mg (30.6%) and
500 mg (30.1%), and the median duration of the continuous
maximum daily dose was 19.6 months (range, 0-38.5 months)
(Table 3). A small proportion (6.4%) of patients received
 2 g/d HU.
Approximately one-third (32.3%) of patients had HU dose adjustments during the post-index period; 26.1% had dose increases,
19.6% had dose decreases, and 14.1% had both increases and decreases. The most common reasons for dose increases or decreases
were lack of efﬁcacy (72.0%) and adverse events (54.5%), respectively (Figure 1). Dose changes were more common among patients
who recently started HU (<1 year from enrollment) (24.4% and
17.6%, respectively) within the 6-month post-index period,
compared with patients who had the disease for a longer duration
(5 years; 5.4% and 4.9%, respectively) (Figure 2).
A total of 257 (18.6%) patients discontinued HU treatment by
the end of the post-index period. Approximately one-quarter
(23.8%; n ¼ 329) of patients had a dose interruption; only 72
(21.9%) of these patients restarted HU during the index period.
The most common reasons for HU dose discontinuation were
adverse events (37.1%) and lack of efﬁcacy (35.5%); the most
common reasons for HU dose interruption were adverse events
(54.5%) and lack of efﬁcacy (22.1%). The majority (81.4%;
n ¼ 1124) of patients who received HU for at least 3 months
continued with HU treatment at the time of data cutoff.
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Table 3 HU Dose Intensity and Exposure
Received HU for ‡ 3 Months
(n [ 1381)
Median maximum daily dose (range),
mg/d

1000.0 (71.4-5571.4)

(Figure 3). Of the 1381 patients who received HU for  3 months,
spleen assessment by physical examination was performed in 973
(70.5%) patients. Of these, 181 (18.6%) had palpable splenomegaly.
Spleen length measurements were available for 66 patients, 27.3% of
whom had spleen length  10 cm from the left costal margin to the
point of greatest splenic extension.

Maximum daily dose, mg/d, n (%)
< 400

91 (6.6)

500

415 (30.1)

750

159 (11.5)

1000

423 (30.6)

1500

204 (14.8)

2000

61 (4.4)

> 2000

28 (2.0)

Median duration of maximum daily
dose, (range), mos

19.6 (0.0-38.5)

Median HU exposure post-index
(range), mos

23.6 (3.1-38.5)

Abbreviation: HU ¼ hydroxyurea.

Laboratory Values and Spleen Assessments
Of the 1381 patients, 57.1% of patients had  1 HCT value
> 45% after receiving HU for 3 months (45.2% of patients
had  2 HCT values > 45%, 37.6% of patients had  3 HCT values
> 45%, and 32.1% of patients had  4 HCT values > 45%).
Approximately one-third (33.1%; n ¼ 457) of patients continued to
receive phlebotomies; 82.9% of these patients requiring phlebotomies continued to report HCT values > 45%. Over one-quarter
(27.4%) of patients had uncontrolled myeloproliferation after being
on HU for  3 months, including 44.9% with  1 WBC count
> 10  109/L and 49.2% with  1 platelet count > 400  109/L

Adverse Events
Of the 1381 patients who received HU for  3 months during the
post-index period, HU-related non-hematologic adverse events
occurred in 7.2% of patients after initiating HU (Table 4). Cytopenias
were reported for 14.6% of patients while on HU; 7.6% had  1 hemoglobin value < 10 g/dL, 7.4% had  1 plateletcount < 100  109/L,
and 1.9% had  1 absolute neutrophil count < 1  109/L.

Hematocrit Control and Cytopenias
Of the 1154 evaluable patients with HCT values < 45% while
on HU, 14.0% had cytopenias at the same time of HCT < 45%;
6.2% had thrombocytopenia (platelet count < 100  109/L), 8.3%
had anemia (hemoglobin < 10 g/L), and 1.9% had neutropenia
(absolute neutrophil count < 1  109/L) (Table 5). A similar
number of cytopenias was observed for patients with  2 HCT
values below 45%.

Discussion
This analysis of REVEAL provides the largest prospective analysis
reported to date of HU treatment patterns in patients with PV.
Results of this analysis showed that in the post-index period, patients who received HU for  3 months were exposed to HU for a
median of 23.6 months, and that the majority (72.1%) of patients
who received HU received 500 to 1000 mg/d; few (6.4%) patients
received the ELN-referenced dose of  2 g/d.13 Approximately

Figure 1 Reasons for HU Dose Adjustment or Discontinuation.a-c aAll Dose Changes, Interruptions, and Discontinuations Were
Summarized Across All Patients During Their Complete HU Exposure. bCohorts Were Not Mutually Exclusive. cAny
Occurrence of Dose Change was Used as the Denominator; the Same Patient Could Contribute to Multiple Dose Adjustments.
d
Interrupted for ‡ 14 Days

Abbreviation: HU ¼ hydroxyurea.
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Figure 2 Proportion of HU Dose Adjustments by Time of HU Start and Exposure

Abbreviation: HU ¼ hydroxyurea. aPre-enrollment; bpost-enrollment.

one-third of patients needed dose increases and/or decreases, and
one-quarter needed dose interruptions, with only 21.9% of patients
restarting after an interruption. Adverse events and lack of efﬁcacy
were the most common reasons for permanent discontinuation of
HU. Over one-half of patients who received HU for  3 months
continued to have elevated HCT values (>45%), and approximately one-third continued to receive phlebotomies or experience
uncontrolled myeloproliferation.
With respect to HU intolerance, when HCT was controlled
(<45%) with HU, 14.0% of patients experienced cytopenias, most
commonly anemia. In addition, a small proportion (7.2%) of patients had nonhematologic adverse events after starting HU. The
adverse events associated with HU in patients enrolled in REVEAL

were consistent with those described in previous publications.15-17
An early report of 100 patients with PV who were treated with
phlebotomy and HU (mean HU dose, 720 mg/d; mean HU
duration, 64.9 months) described 1 patient with skin toxicity
(allergic rash); no clinically signiﬁcant GI toxicity, infection, or
cytopenias, were observed.15 A later prospective study randomized
patients with PV to treatment with HU (n ¼ 150; initiated at
25 mg/kg/d and maintained at 10-15 mg/kg/d) or pipobroman
(n ¼ 142).16 Of the patients who received HU, 133 had > 2 years
of follow-up. Stomatitis was reported in 13/133 (10%), leg ulcers in
12/133 (9%), dry skin/acne in 10/133 (7%), gastric pain/diarrhea
in 9/133 (7%), and cystitis in 3/133 (2%) of these patients. A more
recent retrospective study of 129 patients with PV (n ¼ 54) or

Figure 3 Uncontrolled Laboratory Values in Patients With PV Who Received HU for ‡ 3 Months

Abbreviations: HCT ¼ hematocrit; HU ¼ hydroxyurea; PLT ¼ platelet; PV ¼ polycythemia vera; WBC ¼ white blood cell. aOf patients with > 1 corresponding laboratory value during the postenrollment period while on HU. Analysis included patients with all 3 laboratory values.
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Table 4 Summary of Toxicitiesa in Patients Treated With HU
for ‡ 3 Months
n (%)
(n [ 1381)

Adverse Event
Nonhematologic

100 (7.2)

Gastrointestinal disorders

89 (6.4)

Aphthous stomatitis

2 (0.1)

Colitis ulcerative

1 (0.1)

Constipation

24 (1.7)

Diarrhea

30 (2.2)

Duodenal ulcer

1 (0.1)

Intestinal perforation

1 (0.1)

Nausea

29 (2.1)

Stomatitis

9 (0.7)

Vomiting

13 (0.9)

Skin and subcutaneous tissue
disorders
Decubitus ulcer

14 (1.0)
1 (0.1)

Skin ulcer

13 (0.9)

Abbreviation: HU ¼ hydroxyurea.
a
These are treatment-emergent adverse events and were not necessarily attributed to HU.

essential thrombocythemia (n ¼ 75) treated with a mean dose of
620 mg/d HU described major events necessitating discontinuation
in 12 patients, including leg ulcers (n ¼ 4), acute leukemias (n ¼ 3),
fever (n ¼ 2), and allergies (n ¼ 2).18 In addition, the drug was
withdrawn for symptomatic anemia in 2 patients receiving
> 20 mg/kg/d HU.
Similar to ﬁndings in this analysis of REVEAL data, doses of HU
reported in the above studies were lower than the current ELNendorsed minimum dose of 2 g/d.13 It is suggested that cumulative exposure to > 1 g/d HU over extended periods (>1 year) may
result in HU-related skin toxicity and may require HU discontinuation,18 potentially contributing to the lower doses of HU
observed. Indeed, adverse events were the predominant reason for
HU dose discontinuation or interruption in REVEAL, although
information on the speciﬁc AEs leading to discontinuation in
REVEAL are not available.

This analysis showed that over one-half of the patients treated with
HU failed to achieve HCT values < 45%. Potential reasons for the
high proportion of patients with HCT > 45% despite treatment with
HU may include development of a more advanced, proliferative
disease in a subset of patients, imminent phlebotomy, a lack of
appropriate upward titration of HU owing to infrequent follow-up,
suboptimal titration of HU, and/or a lack of comfort on the part of
the physician or patient with titrating up to 2 g/d. The lack of upward
titration may be related to lingering concerns about HU’s role in
the risk of transformation into myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML).19 Patients with PV are at increased
risk of developing acute leukemia, partly as a complication of
their disease and partly as a result of the cumulative effects of treatments for PV.20-22 A recent propensity-matched analysis of patients
with PV who received phlebotomy (n ¼ 342; median follow-up ¼
29.9 months) or HU (n ¼ 681; median follow-up 34.7 months)
reported 2 patients receiving phlebotomy and 1 patient receiving HU
transformed to acute leukemia.12 Similarly, in a nested case-control
study of 162 patients with MPNs (110/162 [68%] PV) who developed AML or myelodysplastic syndrome and 242 matched control
patients with MPNs (176/242 [73%] PV), 25% of patients with
MPNs who developed AML/MDS were not exposed to cytotoxic
therapy, which supports a role for nontreatment-related factors. A
larger analysis of patients with PV (n ¼ 1545) likewise found no
association between HU use and transformation to AML.23 In
addition, the risk of AML/MDS development was associated with
high exposures of radioactive phosphorus and alkylators but not with
HU treatment, even when administered at high doses.24 Despite this
evidence, the lingering concern surrounding the leukemogenicity of
HU may continue to lead to less aggressive upward titration, even in
the context of uncontrolled HTC.
Limitations of this analysis include that it is an exploratory subgroup analysis, with a relatively short observation period, variable
durations of disease and/or treatment, variance in the doses of HU
used, and the potential confounding effect of age-related adverse
events. In addition, reported proportions of patients with increased/
decreased laboratory values may be underestimated, as the analyses
were performed on patients with  1 laboratory value, and not all
patients had the same number of laboratory value assessments.

Conclusions
Table 5 HCT Control and Cytopenias in Patients Treated With
HU for ‡ 3 Monthsa
Received HU, n/N (%)
(n [ 1300)

Variable
HCT evaluable

1299/1300 (99.9)

 1 HCT value < 45%

1154/1299 (88.8)

Cytopenias at same time of
HCT < 45%

162/1154 (14.0)

PLT count < 100  10 /L

71/1151 (6.2)

HGB < 10 g/L

96/1153 (8.3)

ANC < 1  109/L

20/1042 (1.9)

9

Abbreviations: ANC ¼ absolute neutrophil count; HCT ¼ hematocrit; HGB ¼ hemoglobin;
HU ¼ hydroxyurea; PLT ¼ platelet.
a
Denominator includes patients with  1 corresponding laboratory value during the postenrollment period while on HU.
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In conclusion, this analysis emphasizes the need for active
management of patients with PV with appropriate HU dose titration to maintain blood count control while monitoring for signs and
symptoms of HU intolerance.

Clinical Practice Points
 National guidelines support the use of HU in high-risk patients

with PV.
 In this study, we investigated HU treatment patterns in patients

with PV.
 Of patients who received HU for  3 months, 32.3% had dose

adjustments, 23.7% had dose interruptions, and 18.6% discontinued HU.
 These results emphasize the need for active management of patients with PV.
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